“Personalized Medicine: Studying individualized disease development mechanisms and identification of individualized treatment candidates”

“Personalized Medicine: Studying individualized disease development mechanisms and identification of individualized treatment candidates”

Thursday, October 4, 2018

14:00

MBG Conference Hall

 

 

Prof. Osman Ugur Sezerman

Acibadem University, Faculty of Medicine

Prof. O. Uğur Sezerman is professor at Biostatistics and Medical Informatics department at Acibadem University, in Istanbul. He received his PhD from Boston University Biomedical Engineering Department where he worked under the guidance of Prof. Charles De Lisi. After he worked as research faculty and founded a biotech company. He joined Sabanci University Biological Sciences and Bioengineering Department in 1999. He established Turkey’s first bioinformatics undergraduate and graduate programmes. He founded the computational biology lab and protein engineering labs at Sabanci University. In 2015 he joined Acibadem University School of Medicine to apply the tools and methods his group developed to problems in medicine with a focus on personalized medicine applications.

Prof. O. Uğur Sezerman’s research interests are personalized medicine, precision medicine, protein engineering, drug and vaccine design, functional genomics, metagenomics, system biology and bioinformatics.

For further details of Prof. Sezermans' cv including list of publications: http://www.sezermanlab.org

Abstract

Recent advancements in “Omics” technologies enabled researchers to look into disease development mechanisms at a cellular level in a cost efficient manner. This also led the way into personalized medicine and precision medicine applications aiming to give the right treatment to the right patient at right dose at the right time.

Our group developed several pathway based analysis approaches to study individualized disease development mechanisms combining genes that are affected via several 2Omics data. We also developed scorings schemes to identify indivualized therapy targets. In this talk I will briefly go over the methods that we developed and give examples of their application to complex diseases such as cancer and Behcet’s disease. We also developed a novel methodology to study Rare diseases which helped us to identify novel genes and novel variants that can be used for diagnostics of these diseases.